12830 EL CAMINO REAL, SAN DIEGO, CA
Stipulation and Agreement of Settlement in Case No.: 3:23-cv-02293-WQH-MSB
Earnings Release
Acadia Pharmaceuticals Approves Amendment to 2024 Equity Incentive Plan
Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Annual Report to Security Holders
Board Appointment - Jonathan M. Poole Joins Acadia Pharmaceuticals Board
Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
S-8 POS